#RubiconResearch #IPOs #sharebazaar
Rubicon Research was incorporated in 1999, Rubicon Research Limited is a pharmaceutical company engaged in the development, manufacturing, and commercialization of differentiated formulations.
As of March 31, 2024, Rubicon Research Limited had a portfolio of 69 active Abbreviated New Drug Application (ANDA) and New Drug Application (NDA) products approved by the US FDA. The company’s portfolio includes 55 commercialized products, with a US generic pharmaceutical market size of USD 2,386.6 million, of which Rubicon Research Limited contributed USD 154.3 million in Fiscal 2024.
The company had 59 active ANDAs as of March 31, 2024, including 14 approvals received in Fiscal 2024. As of the same date, 47 commercialized products were being marketed and sold in the US, including seven specialty products. This excludes products in Validus’ portfolio before its acquisition by Rubicon Research Limited. Additionally, 19 new applications were under review by the US FDA for ANDA approval.
Rubicon Research IPO details confirmed | RHP details | IPO latest news | IPO Review
As of March 31, 2024, the company marketed over 250 SKUs to 101 customers, including three major wholesalers who, account for more than 90% of wholesale drug distribution in the US. The company also supplies group purchasing organizations (GPOs), national pharmacy chains, regional pharmacy chains, and managed care organizations.
Rubicon Research Limited, directly or through its subsidiaries, had 59 active ANDAs and 10 active NDAs (acquired through Validus) approved by the US FDA. The company’s products are marketed in the US through wholly owned subsidiaries, AdvaGen Pharma and Validus, with some products distributed by third-party distributors. As of March 31, 2024, 79.71% of ANDAs had been commercialized. Through the acquisition of Validus in February 2024, the company markets two brands in the CNS therapy area.
Beyond the US market, Rubicon Research Limited, directly or through third-party distribution partners, has registered or filed 16 product applications across Australia, the United Kingdom, Singapore, Saudi Arabia, and the United Arab Emirates and expects to commence commercial activities upon approval. The company also provides contract manufacturing services to select customers in India, Australia, and New Zealand.
Rubicon Research Limited operates two manufacturing facilities and may expand further to enhance manufacturing capabilities. The Ambernath, Maharashtra facility, covering 14,250m², manufactures oral solid dosages and unit-dose, bi-dose, and multi-dose nasal sprays. The Satara, Maharashtra facility, covering 4,050m², is used for manufacturing oral liquid dosages.
Rubicon Research IPO details confirmed | RHP details | IPO latest news | IPO Review
As of March 31, 2024, Rubicon Research Limited employed 903 personnel, including 143 scientists, and engaged 499 contractual personnel across operations in India, the US, and Canada. In the previous years, 400 contractual personnel were engaged in 2023 and 338 in 2022.
Rubicon Research IPO details confirmed | RHP details | IPO latest news | IPO Review
Информация по комментариям в разработке